Related Experiment Video
Updated: May 28, 2026

A Platform of Anti-biofilm Assays Suited to the Exploration of Natural Compound Libraries
Published on: December 27, 2016
Repurposing Non-Infectious Therapeutic Agents to Aid in the Treatment of Chronic Biofilm Infections
Lila Berle1,2, Yash Sodhi3, Poonam Mathur4
1University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Abstract:
Antibiotics primarily exert their effect on planktonic microbial states, limiting their ability to eradicate biofilms commonly seen in chronic infections. This is because the minimal inhibitory concentration of antibiotics needed to kill microbes in biofilms can be up to 1000 times greater than when microbes are in their planktonic state. Yet up to 70% of all chronic infections are associated with a biofilm component. Consequently, novel therapeutics are needed to aid in the treatment of chronic biofilm infections. One such approach is to repurpose drugs that have demonstrated safety for non-infectious clinical indications. The main advantage of this approach is that the agents have already been shown to be safe for human administration, which can expedite clinical trial development of agents for biofilm infections. Unfortunately, most clinicians are unaware of the antimicrobial properties of some commonly used drugs. Thus, the aim of this Perspective was to discuss the potential of four drugs that have theoretical promise as adjuvants in the treatment of chronic biofilm infections. This was accomplished by providing detailed discussion of each agent with respect to current clinical use, potential mechanisms of antimicrobial activity, and present data to support use as adjuvant biofilm agents.
Insights
Novel therapeutics are needed to combat biofilms in chronic infections, as antibiotics are less effective. Repurposing existing safe drugs offers a promising strategy to develop new adjuvant biofilm treatments.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Antibiotics are less effective against microbial biofilms, which are implicated in up to 70% of chronic infections.
- Biofilm-dwelling microbes require significantly higher antibiotic concentrations (up to 1000x) compared to planktonic forms.
- There is a critical need for novel therapeutic strategies to effectively treat chronic biofilm infections.
Purpose of the Study:
- To explore the potential of repurposing existing drugs as adjuvant therapies for chronic biofilm infections.
- To identify and discuss four drugs with theoretical promise for treating biofilm infections.
- To highlight the advantages of using already-approved drugs for expedited clinical development.
Main Methods:
- Reviewing current clinical applications of selected drugs.
- Investigating potential antimicrobial mechanisms of action for each drug.
- Compiling existing data supporting their use as adjuvant biofilm agents.
Main Results:
- Four drugs were identified with theoretical promise as adjuvant biofilm agents.
- Detailed discussions included current clinical use and proposed antimicrobial activities.
- Evidence was presented to support their potential role in combating biofilms.
Conclusions:
- Repurposing safe, non-antimicrobial drugs is a viable strategy for developing new biofilm infection treatments.
- Clinicians need greater awareness of the antimicrobial potential of commonly used medications.
- Further research and clinical trials are warranted to validate these repurposed drugs as adjuvant biofilm therapies.
Related Concept Videos
Biofilms
Biological Methods for Microbial Control
Gene Regulation in Microbial Communities: Quorum Sensing
Combined Effects of Drugs: Synergism
Such synergistic combinations...

